Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Otilimab (GSK3196165) in RA (contRAst 3)
NCT04134728Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2019
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of otilimab in rheumatoid arthritis (RA) (6 arms), sponsored by GSK. Primary endpoint: Percentage of Participants With 20% Improvement in American College of Rheumatology Criteria at 12 weeks. Started Oct 2019; status: completed.
02
Drugs
otilimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04134728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04134728.